KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.92), $0.04 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $7.17 million.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)